Added to YB: 2026-04-03
Pitch date: 2026-04-02
PRTC [neutral]
PureTech Health plc
Author Info
The Oak Bloke shares analysis of the UK stock market, particularly overlooked small caps. Sign up for the newsletter.
Company Info
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States.
Market Cap
GBP 346.6M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-1.39
P/E
7.07
EV/Sales
26.91
Sector
Biotechnology
Category
growth
Perfect PRTC makes Perfection
PRTC (update): Seaport (35% owned) Phase 1 GlyphAgo hit 6.8x bioavailability vs 2x target, de-risking liver toxicity that blocked US approval; moving to Phase 2b registration-enabling trial for anxiety. LYT-100 (wholly owned) peer-reviewed in AJRCCM showing 80.9% efficacy vs 54.1% for pirfenidone in IPF; Phase 3 starting 2026 targeting $20B TAM. Trading £274M cap w/ £240M cash + £225M Cobenfy milestones.
Read full article (5 min)